Phase III studies with more patients per site are likely, ACIL meeting is told.
PHASE III STUDIES WITH MORE PATIENTS PER SITE will become more common, Future Health Care Research Centers President Timothy Ross predicted at a Feb. 1 meeting of ACIL, the Association of Independent Scientific, Engineering and Testing Firms, in Arlington, Va. "You're not going to see in the future 100, 200-site trials," Ross predicted. "You might have the same patient target, but I think our site industry has to raise up and recruit more patients per site in the same time period or less of a time period....That's where the industry starts picking up some phenomenal time savings and cost savings."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth